Farallon Capital Management 13F: Adds $25M to PTGX Stake

Farallon Capital Raises Stake in Protagonist Therapeutics

Farallon Capital Management boosted its holdings in Protagonist Therapeutics, Inc. (NasdaqGM: PTGX) by acquiring an additional 204,900 shares during the period. According to its latest Form 13F filing with the SEC, which reflects holdings as of the reporting period and may not represent the investor's current position, the prominent fund grew its stake by 3.3%. That brings Farallon's total ownership to 6,348,906 shares, valued at roughly $778.2 million based on market values.

Inside Farallon's Position Change

Prior to the adjustment, Farallon held 6,144,006 shares of the biotechnology company. The addition of 204,900 shares marks a 3.3% increase in the fund's investment size. Because 13F filings look backward at portfolio snapshots submitted weeks after a quarter ends, the exact current value of these shares shifts alongside daily market trading.

Protagonist Therapeutics Stock Performance

Protagonist Therapeutics shares recently traded at $122.58, sitting well within its 52-week range spanning from a low of $62.24 to a high of $160.81. The biotechnology firm carries a price-to-earnings ratio of 140.76 based on trailing results, alongside a beta of 1.79 indicating sharper price swings than the broader market. Its 50-day moving average rests at $143.91, while the 200-day moving average stands at $108.98.

Analysts Set New Price Targets

Wall Street firms maintain an active view on Protagonist Therapeutics, led by a consensus recommendation of strong buy and a mean price target of $174.69 across 13 analyst opinions. On October 12, 2026, UBS initiated coverage on the stock with a buy rating and a $184.00 price target. Earlier, on September 1, 2026, Barclays maintained an overweight rating while lifting its target to $180.00 from $153.00. BMO Capital also maintained an outperform rating on September 1, 2026, raising its target to $190.00 from $178.00.

What Protagonist Therapeutics Does

Protagonist Therapeutics, Inc. is a Newark, California-based clinical-stage biopharmaceutical company focused on discovering and developing peptide-based drugs for unmet medical needs. Its pipeline includes investigational treatments targeting plaque psoriasis, rare blood disorders, and obesity. The company operates within the healthcare sector with a modest team of 141 employees.

What to Watch at Protagonist Therapeutics, Inc.

Investors tracking Farallon Capital's footprint and Protagonist Therapeutics will look toward the company's next earnings report scheduled for November 5, 2026. Subsequent quarterly 13F filings from institutional managers will also reveal whether Farallon continues adding to its position or holds steady. These disclosures remain historical records and do not guarantee current portfolio allocations.